Craneware (LON:CRW) Sets New 52-Week High at $2,278.00

Craneware plc (LON:CRW) hit a new 52-week high on Wednesday . The stock traded as high as GBX 2,278 ($28.14) and last traded at GBX 2,275 ($28.10), with a volume of 50163 shares traded. The stock had previously closed at GBX 2,230 ($27.54).

Analysts Set New Price Targets

Separately, Berenberg Bank raised their target price on Craneware from GBX 2,300 ($28.41) to GBX 2,600 ($32.11) and gave the stock a “buy” rating in a research report on Monday, March 4th.

Craneware Price Performance

The company has a debt-to-equity ratio of 19.15, a quick ratio of 1.00 and a current ratio of 0.78. The firm has a market cap of £791.84 million, a price-to-earnings ratio of 10,666.67 and a beta of 0.14. The firm has a 50-day moving average price of GBX 2,178.99 and a two-hundred day moving average price of GBX 1,903.64.

Craneware Cuts Dividend

The firm also recently announced a dividend, which was paid on Monday, April 15th. Stockholders of record on Thursday, March 21st were given a dividend of GBX 13 ($0.16) per share. This represents a dividend yield of 0.62%. The ex-dividend date of this dividend was Thursday, March 21st. Craneware’s dividend payout ratio (DPR) is presently 13,809.52%.

Craneware Company Profile

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors.